What are alternative medications to RINVOQ (brexpiprazole) for its indicated uses?

RINVOQ Alternatives

There appears to be a critical error in the question: RINVOQ (upadacitinib) is a JAK inhibitor used for inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease—NOT brexpiprazole, which is an atypical antipsychotic. The provided evidence discusses brexpiprazole for psychiatric conditions and Alzheimer's-related agitation, which are completely different therapeutic areas from RINVOQ's indications. I will address alternatives for brexpiprazole based on the available evidence, as this appears to be the intended question.

Alternatives for Schizophrenia

For schizophrenia treatment, other atypical antipsychotics represent the primary alternatives to brexpiprazole, with selection based on side effect profiles and patient-specific factors.

First-Line Atypical Antipsychotics

• Aripiprazole shares brexpiprazole's dopamine D2 partial agonist mechanism but differs in receptor affinity profiles, showing comparable efficacy for acute psychotic symptoms 1, 2
• Risperidone at initial dosages of 0.25 mg/day (maximum 2-3 mg/day) for control of delusions, hallucinations, and severe agitation, with lower risk of extrapyramidal symptoms than typical antipsychotics 3
• Olanzapine starting at 2.5 mg/day (maximum 10 mg/day), generally well-tolerated but associated with metabolic concerns 3
• Quetiapine at 12.5 mg twice daily (maximum 200 mg twice daily), more sedating with risk of orthostatic hypotension 3
• Lurasidone and cariprazine as newer alternatives with improved metabolic profiles and potential benefits for negative symptoms, though cariprazine carries higher akathisia risk 4

Important Considerations

• Brexpiprazole demonstrates similar efficacy to aripiprazole and quetiapine but with distinct receptor binding profiles that may influence tolerability 1
• The 2025 INTEGRATE guidelines recommend switching to antipsychotics with more benign metabolic profiles (such as aripiprazole or ziprasidone) when metabolic side effects emerge 3
• For patients with inadequate response, clozapine remains the gold standard for treatment-resistant schizophrenia 3

Alternatives for Major Depressive Disorder (Adjunctive Treatment)

For adjunctive treatment of major depressive disorder, other atypical antipsychotics and antidepressant augmentation strategies serve as alternatives.

Atypical Antipsychotic Augmentation

• Aripiprazole as the most closely related alternative, approved for MDD augmentation with similar dopamine partial agonist properties 2, 5
• Quetiapine (extended-release formulation) approved for MDD augmentation 3

Antidepressant Optimization

• SSRIs including sertraline (25-50 mg/day, maximum 200 mg/day) with better tolerability and fewer drug interactions, or citalopram (10 mg/day, maximum 40 mg/day) 3
• SNRIs such as venlafaxine (37.5 mg once or twice daily, maximum 225 mg/day) or duloxetine (30 mg once daily, maximum 60 mg twice daily) for patients requiring dual serotonin-norepinephrine action 3
• Tricyclic antidepressants like nortriptyline (10 mg at bedtime, maximum 40 mg/day) or desipramine (10-25 mg in morning, maximum 150 mg/day) for refractory cases, though with more side effects 3

Alternatives for Agitation in Alzheimer's Disease

For agitation associated with Alzheimer's dementia, brexpiprazole is the only FDA-approved medication, but several off-label alternatives exist with varying evidence.

Atypical Antipsychotics (Off-Label)

• Risperidone at very low doses (0.25 mg/day at bedtime, maximum 2-3 mg/day) for severe agitation, delusions, and combativeness, though with diminished but present extrapyramidal symptom risk 3
• Olanzapine (2.5 mg/day at bedtime, maximum 10 mg/day) generally well-tolerated for behavioral symptoms 3
• Quetiapine (12.5 mg twice daily, maximum 200 mg twice daily) with more sedating properties 3

Critical Warning: All antipsychotics carry a black box warning for increased mortality in elderly patients with dementia-related psychosis 6. Brexpiprazole may be prioritized over off-label alternatives given its specific FDA approval for this indication 6.

Mood Stabilizers and Antidepressants

• Trazodone (25 mg/day, maximum 200-400 mg/day in divided doses) as an alternative for agitation control, though with cardiac precautions 3
• Divalproex sodium (125 mg twice daily, titrated to therapeutic levels of 40-90 mcg/mL) generally better tolerated than other mood stabilizers for severe agitated behaviors 3
• SSRIs for patients with co-occurring depression and agitation, particularly citalopram or sertraline 3

Non-Pharmacological Approaches

• Environmental interventions including structured activities, reassurance, socialization, and caregiver education should accompany any medication trial 3
• Behavioral interventions may reduce or eliminate medication need in mild agitation 3

Key Safety Monitoring

• Metabolic parameters: BMI, waist circumference, blood pressure, HbA1c, glucose, and lipids should be checked at baseline, weekly for 6 weeks, at 3 months, and annually 3
• Movement disorders: Monitor for akathisia (particularly with brexpiprazole 2-4 mg doses), which may require dose reduction or propranolol 10-30 mg 2-3 times daily 3
• Cardiovascular effects: ECG monitoring recommended at baseline, especially in elderly patients 3